Liu CH, Yang SS, Peng CY, et al. - The performance of glecaprevir/pibrentasvir (GLE/PIB) was investigated in patients with chronic kidney disease (CKD) stage 4 or 5 in Taiwan. At 4 academic centers in Taiwan, researchers performed retrospective recruitment of 108 chronic hepatitis C virus (HCV) patients with CKD stage 4 (n = 32) or 5 (n = 76) who were receiving GLE/PIB for 8-12 weeks. Sustained virologic response at off-therapy week 12 (SVR12) for evaluable (EP) and per-protocol populations (PP) was determined to ascertain the effectiveness. EP and PP analyses revealed the SVR12 rate of 99.1% (107 of 108 patients) and 100% (107 of 107 patients). Patients with CKD stage 4 and 5 had the SVR12 rates of 100% (95% CI: 89.3%-100%) and 98.7%, respectively. Pruritus (19.4%), fatigue (15.7%) and nausea (13.9%) were the three most common adverse events. Findings thereby suggest GLE/PIB for 8-12 weeks as effective and well-tolerated in HCV patients with severe RI.